Abstract:Kinase inhibition is an increasingly popular strategy for pharmacotherapy of human diseases. Although many of these agents have been described as "targeted therapy", they will typically inhibit multiple kinases with varying potency. Pre-clinical model testing has not predicted the numerous significant toxicities identified during clinical development. The purpose of this study was to develop a bioinformatics-based method to predict specific adverse events (AEs) in humans associated with the inhibition of particular kinase targets (KTs).The AE frequencies of protein kinase inhibitors (PKIs) were curated from three sources (PubMed, Thompson Physician Desk Reference and PharmGKB), and affinities of 38 PKIs for 317 kinases, representing >50% of the predicted human kinome, were collected from published in vitro assay results. A novel quantitative computational method was developed to predict associations between KTs and AEs that included a whole panel of 71 AEs and 20 PKIs targeting 266 distinct kinases with K(d)<10microM. The method calculated an unbiased, kinome-wide association score via linear algebra on (i) the normalized frequencies of AEs associated with 20 PKIs and (ii) the negative log-transformed dissociation constant of kinases targeted by these PKIs. Finally, a reference standard was calculated by applying Fisher's exact test to the co-occurrence of indexed Pubmed terms (p0.05, and manually verified) for AE and associated kinase targets (AE-KT) pairs from standard literature search techniques. We also evaluated the enrichment of predictions between the quantitative method and the literature search by Fisher's exact testing.We identified significant associations among already empirically well established pairs of AEs (e.g. diarrhea and rash) and KTs (e.g. EGFR). The following less well recognized AE-KT pairs had similar association scores: diarrhea-(DDR1;ERBB4), rash-ERBB4, and fatigue-(CSF1R;KIT). With no filtering, the association score identified 41 prioritized associations involving 7 AEs and 19 KTs. Among them, eight associations were reported in the literature review. There were only 78 out of a total of 4522 AE-KT pairs meeting the evaluation threshold, indicating a strong association between the predicted and the text mined AE-KT pairs (p=3x10(-7)). As many of these drugs remain in development, a larger volume of more detailed data on AE-PKI associations is accessible only through non-public databases. These prediction models will be refined with these data and validated through dedicated prospective human studies. CONCLUSION AND FUTURE DIRECTIONS: Our in silico method can predict associations between kinase targets and AE frequencies in human patients. Refining this method should lead to improved clinical development of protein kinase inhibitors, a large new class of therapeutics. http://www.lussierlab.org/publication/PAS/.

In Vitro Assessment of Inhibitory Effects of Kinase Inhibitors on CYP2C9, 3A and 1A2: Prediction of Drug-Drug Interaction Risk with Warfarin and Direct Oral Anticoagulants

Prediction of the likelihood of drug interactions with kinase inhibitors based on in vitro and computational studies.

Tyrosine kinase inhibitors and direct oral anticoagulants: In vitro evaluation of drug–drug interaction mediated by P‐glycoprotein

Risk assessment and molecular mechanism study of drug-drug interactions between rivaroxaban and tyrosine kinase inhibitors mediated by CYP2J2/3A4 and BCRP/P-gp

Application of Physiologically Based Pharmacokinetic Modelling for the Prediction of Drug–drug Interactions Involving Anlotinib As a Perpetrator of Cytochrome P450 Enzymes

Drug-Drug Interaction Potentials of Tyrosine Kinase Inhibitors Via Inhibition of UDP-Glucuronosyltransferases

Identification of Infigratinib as a Potent Reversible Inhibitor and Mechanism-Based Inactivator of CYP2J2: Nascent Evidence for a Potential In Vivo Metabolic Drug-Drug Interaction with Rivaroxaban

Kinase inhibition-related adverse events predicted from in vitro kinome and clinical trial data.

Predicting Drug-Drug Interaction with Physiologically Based Pharmacokinetic/Pharmacodynamic Modelling and Optimal Dosing of Oral Anti-Coagulants with Dronedarone Co-Administration

Evaluation of the drug–drug interaction potential of brigatinib using a physiologically‐based pharmacokinetic modeling approach

Anlotinib and Fruquintinib Co-Administrated with Warfarin Increases the Risk of Bleeding: Studied from Pharmacokinetic and Pharmacodynamic Perspectives

In Vitro Assessment of Pharmacokinetic Drug-Drug Interactions of Direct Oral Anticoagulants: Type 5-Phosphodiesterase Inhibitors Are Inhibitors of Rivaroxaban and Apixaban Efflux by P-Glycoprotein

Application of Physiologically Based Pharmacokinetic Modeling to the Prediction of Drug-Drug and Drug-Disease Interactions for Rivaroxaban

Quantitative prediction and clinical observation of a CYP3A inhibitor-based drug-drug interactions with MLN3897, a potent C-C chemokine receptor-1 antagonist

Prediction of Drug–Drug Interactions with Ensartinib As a Time-Dependent CYP3A Inhibitor Using Physiologically Based Pharmacokinetic Model

Modeling the complexity of drug-drug interactions: A physiologically-based pharmacokinetic study of Lenvatinib with Schisantherin A/Schisandrin A

Predicting Drug-Drug Interactions with Physiologically Based Pharmacokinetic/pharmacodynamic Modelling and Optimal Dosing of Apixaban and Rivaroxaban with Dronedarone Co-Administration

Pathway-Dependent Inhibition of Paclitaxel Hydroxylation by Kinase Inhibitors and Assessment of Drug–Drug Interaction Potentials

Projections of Drug-Drug Interactions Caused by Time-Dependent Inhibitors of Cytochrome P450 1A2, 2B6, 2C8, 2C9, 2C19, and 2D6 Using In Vitro Data in Static and Dynamic Models

Predicting drug-drug interaction with physiologically based pharmacokinetic/pharmacodynamic modelling and optimal dosing of apixaban and rivaroxaban with dronedarone co-administration

Potential risk of drug-drug interactions of ponatinib via inhibition against human UDP-glucuronosyltransferases